Compare · CRTX vs EXEL
CRTX vs EXEL
Side-by-side comparison of Cortexyme Inc. (CRTX) and Exelixis Inc. (EXEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRTX and EXEL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- EXEL carries a market cap of $15.77B.
- EXEL has hit the wire 6 times in the past 4 weeks while CRTX has been quiet.
- EXEL has more recent analyst coverage (25 ratings vs 9 for CRTX).
- Company
- Cortexyme Inc.
- Exelixis Inc.
- Price
- -
- -
- Market cap
- -
- $15.77B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2000
- News (4w)
- 0
- 6
- Recent ratings
- 9
- 25
Cortexyme Inc.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Exelixis Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Latest CRTX
- Cortexyme Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 4: Monohon Ted covered exercise/tax liability with 1,640 shares, decreasing direct ownership by 5% to 29,311 units to cover taxes
- SEC Form 10-Q filed by Cortexyme Inc.
- Cortexyme Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 4: Monohon Ted covered exercise/tax liability with 1,520 shares, decreasing direct ownership by 5% to 30,951 units to cover taxes
- Cortexyme Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Stocks That Hit 52-Week Lows On Thursday
- Recap of Wednesday's Biotech Catalysts - End of The Day Summary
- Stocks That Hit 52-Week Lows On Wednesday
- Cortexyme Corporate Name Change To Quince Therapeutics To Take Effect On August 1, 2022
Latest EXEL
- FDA Approval for CABOMETYX issued to EXELIXIS INC
- FDA Approval for COMETRIQ issued to EXELIXIS
- Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
- SEC Form SCHEDULE 13G filed by Exelixis Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Exelixis Inc.
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
- SEC Form 10-Q filed by Exelixis Inc.
- SEC Form 8-K filed by Exelixis Inc.
- Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
- Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026